Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial-Reference-Cited by-同舟云学术

Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial

Published:2013-12 Issue:6 Volume:64 Page:873-875
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Arsov Christian,Becker Nikolaus,Hadaschik Boris A.,Hohenfellner Markus,Herkommer Kathleen,Gschwend Jürgen E.,Imkamp Florian,Kuczyk Markus A.,Antoch Gerald,Kristiansen Glen,Siener Roswitha,Semjonow Axel,Hamdy Freddie C.,Lilja Hans,Vickers Andrew J.,Schröder Fritz H.,Albers Peter

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Prostate-cancer mortality at 11 years of follow-up;Schröder;N Engl J Med,2012

3. Screening for prostate cancer decreases metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC);Schröder;Eur Urol,2012

4. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years;Lilja;J Clin Oncol,2007

5. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging;Fang;Urology,2001

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preliminary effects of risk-adapted PSA screening for prostate cancer after integrating PRS-specific and age-specific variation;Frontiers in Genetics;2024-08-01

2. Prostate Cancer Screening in Young Men;Journal of Personalized Medicine;2024-07-31

3. Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial;European Urology;2024-05

4. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer;European Urology Oncology;2023-12

5. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial;European Urology;2023-10